Dr Reddy's Labs

Here's why Dr. Reddy's share slipped 8%, hit 52-week low on Monday, April 7

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Dr Reddy's gets over Rs 2,395 crore show cause notice from I-T authority

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

Dr Reddy's Labs Q3 results: PAT rises 2.5% at Rs 1,413 cr, revenue up 16%

The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets

Dr Reddy's declines 3% after China's regulator bans import of ADHD drug

Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.

Dr Reddy's Lab says its Andhra plant gets two observations from USFDA

Dr Reddy's Laboratories Ltd on Thursday said the US health regulator has issued Form 483 with two observations after inspecting its manufacturing facility located at Srikakulam in Andhra Pradesh. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The US Food and Drug Administration (USFDA) completed a pre-approval inspection at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh on Thursday, Dr Reddy's said in a regulatory filing. The inspection was conducted from June 30, 2022 to July 7, 2022. "We have been issued a Form 483 with two observations, which we will address within the stipulated timeline," the company added.

Dr Reddy's subsidiary inks pact with US-based Olema Pharmaceuticals

Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of a target

Dr Reddy's seeks nod for phase-3 trial of Sputnik Light as booster dose

Sputnik Light has not yet received emergency use authorisation from the DCGI

Top trading ideas by Ajit Mishra: Buy Asian Paints, IDFC First Bank

The overall chart pattern of Asian Paints indicates that the prevailing momentum is likely to continue

Dr Reddy's reclaims spot as India's 2nd most valuable pharma company

At 02:17 pm, Dr Reddy's Labs market cap stood at Rs 90,348 crore while that of Divi's Laboratories stood at Rs 89,119 crore, BSE data show

Dr Reddy's Labs advances 4%, hits a record high on healthy Q1 numbers

The company's consolidated revenues rose 15 per cent to Rs 4,418 crore, mainly due to growth in US formulations

Market Ahead, May 11: Top factors that could guide markets this week

Around 50 companies including the likes of Maruti Suzuki, Nestle, Dr Reddy's Labs, Biocon, and Bandhan Bank are scheduled to announce their March quarter results.

PSAI segment decline pulls down Dr Reddy's Q1 show

Earnings were driven by one-off gains

US Supreme Court allows Dr Reddy's Labs to sell generic Suboxone film

The potential revenue upside from the sale of generic Suboxone is expected to be substantial for Dr Reddy's when it resumes sales

US court rules in favour of Dr Reddy's, allows sale of generic Suboxone

According to market reports, suboxone had sales of around $1.86 billion in the US for the 12 months ended April

A few bright spots for Dr Reddy's; stock is back on investors' radar

Stability in American business, new launches key as firm targets to double US portfolio in five years

Dr Reddy's enters $ 71 mn market with launch of anti-allergy drug in US

BS ReporterHyderabad, 16 March: Dr Reddy's Laboratories Limited announced today that it has launched Levocetrizine Dihydrochloride tablets, an over-the counter(OTC) therapeutic equivalent generic version of Xyzal Allergy tablets in the US market as approved by the US Food and Drug Administration(US FDA).The drug is an antihistamine used for 24-hour relief of allergy symptoms such as watery eyes, runny nose, itching eyes and nose and sneezing."This first-to-market launch for the store brand is the testament to the deep capabilities of our store brand OTC business,"said Milan Kalawadia, vice president and head, US OTC and Specialty Rx business at Dr Reddy's Laboratories. "We look forward to collaborating with our customers to bring high-quality, affordable store brand alternatives to the market."The Xyzal Allergy brand had US sales of approximately $ 71 million for the most recent twelve months ending in January 2018, according to the company. Xyzal is a registered trademark of UCB ...

Dr Reddy's gains 6% in two days post clarification on regulatory issues

The stock moved higher by 3% to Rs 2,473, extending its Thursday's 3% gain on BSE.

Dr Reddy's shines on favourable patent verdict

Launch of narcotic treatment drug may be sometime away, but it enhances earnings visibility

No immediate respite seen for Dr Reddy's

Even as not much was expected from Dr Reddy's March quarter results, the higher than estimated decline in profitability was a disappointment. With US FDA related issues remaining unresolved, the near-term outlook continues to be subdued. Revenues at Rs 3,554 crore for March quarter were down five per cent year-on-year, and came lower than Rs 3,683 crore estimated by analysts polled by Bloomberg. This was the fifth consecutive quarterly decline on a year-on-year basis, in revenues. Earnings before interest, tax, depreciation and amortisation (Ebitda) at Rs 630.3 crore was short by a bigger margin as compared to expectations of Rs 779 crore. Consequently, net profit at Rs 312.5 crore was significantly lower than estimates of Rs 385 crore. The major pressure point continues to be US sales. With the company's three Indian facilities under US FDA's warning letter, approvals for new product launches have been delayed thereby impacting the company's growth. Since US generic sales contribute .

USFDA completes inspection of Dr Reddy's Srikakulam SEZ unit

USFDA recently issued Form 483 with two observations to DRL's another API facility at Srikakulam